Presenter's Information
Seung-Jung Park, MD
Country | Korea (Republic of) |
Specialty | Interventional Cardiologist |
- 15 Years' Journey of AMC TAVR
- The PREVENT Trial: Confirmative RCT of Preventive PCI of Vulnerable Plaque
- Case 1. Practical Issue of Left Main & Multi-Vessel PCI: Make it Simple!
- Revascularization for Left Main Disease: Updated Data, Global Guidelines and Beyond
- LM PCI: Make-It-Simple!
- What Really Matters in LM Bifurcation PCI: Concept or Technique?
- 10 Year's Journey of AMC TAVR
- PREVENT Trial
- Functionally Insignificant Vulnerable Plaque; Treat or Not?
- Non-LM Bifurcation PCI in 2023: Don't Touch Small Side Branch, Evolving Changes in AMC Practice
- Insight from All Data for Triple Vessel Disease
- Don't Touch Small Side Branch! Concept Changes After ISCHEMIA Study
- My Approach to Multi-vessel Disease - Master\'s Skill Secret
- Non-LM Bifurcation Revascularization 2022: Guidelines and Concept Change
- The Last 10 Year TAVR Path and Achievement of ASAN MEDICAL CENTER
- Updated Techniques and Concepts 2021 for Complex Left Main PCI
- Why Mismatching? FFR vs. Angiographic %DS
- Minimalist TAVR: AMC Experience
- What Is the Practical Approach to LM/MVD Revascularization? - Make It Simple!!
- PREVENT: Physiology and Imaging for PREVENTing Future Events
- [Debate: Should All CTOs Be Opened?] Cons
- MAIN COMPARE: 10-Year Follow-up
- What Is the Benefit of CTO PCI?: Insights from the DECISION CTO
- Physiology-Guidance: Synergetic Hybrid Approach for Complex PCI
- 10-year Outcomes of MAIN-COMPARE Study: Main and Key Substudies
- [Featured Lecture] LM-PCI: New Techniques, Concept, and Insights from the LM Pioneer
- PCI vs CABG for Left Main and Multivessel Disease
- Integrated Use of FFR and IVUS in LM PCI
- TAVR in Asia, Korea, and AMC
- PREVENT Trial: Update and Interesting Cases
- The Lesson from DECISION-CTO Trial
- All the Data from IRIS-FFR Registry
- To Treat or Not to Treat for Gray Zone FFR(0.76-0.80)
- [Debate: Should All CTOs Be Opened?] Con
- Top 10 Tips on Left Main PCI
- Keynote Lecture on Left Main PCI: Expert\'s Concept and Technique
- Future Perspective of Bioresorbable Vascular Scaffolds (ABSORBII, ABSORBIII, AIDA-AMC Registry) : Is It a Crisis or a Chance to Move Forward?
- Can BRS Stabilize Vulnerable Plaque?: PREVENT
- [Debate: Left Main Disease - How to Treat in Contemporary Era?] LM Is No Longer Surgical Disease.
- How To Manage Grey Zone FFR?: Data from IRIS FFR Registry
- Impact of Complete Revascularization for Multivessel PCI
- PREVENT Trial: Update and Insight from Plaque Imaging
- Impact of Complete Revascularization for MVD PCI
- Why PCI ? - Rationale for PCI / - Patient & Lesion Selection
- Is It a Matter of Technique or Concept?: Left Main and Bifurcation PCI
- From STABLE to PREVENT
- FFR and Clinical Outcomes: Evidence Has Never Been Stronger
- Left Main PCI: The Simpler, The Better
- Case 1: Left Main Disease
- Left Main & Bifurcation PCI: Is It a Matter of Technique or Concept?
- Relationship Between FFR and Clinical Outcome: Data from IRIS-FFR Registry
- Can We Prevent Events of Vulnerable Plaques?: From STABLE to PREVENT
- FFR: How to Change Our Practice?
- Integrated Approach for LM PCI Using IVUS and FFR
- What Happened in Deferred Lesion: Insight from IRIS-FFR Registry
- Please Keep It: IVUS-Guidance for LM Stenting
- Left Main Disease Is Not Surgical Treatment Any More: Data-Supported 2015
- Fate of Deferred Lesion: Insight from Prospective IRIS-FFR Registry
- Plaque Stabilization and Preemptive BVS: From STABLE to PREVENT
- How to Treat? - Functionally Insignificant Vulnerable Plaque: STABLE and PREVENT
- Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease
- Can We Prevent Future Event?: PREVENT Trial - Design and Rationale
- Impact of FFR
- IVUS Is Enough!
- How Good FFR Guided in Real Practice from Asan PCI and Multivessel Registry & IRIS-FFR Registry
- Can We Prevent DEFER Lesion Event? PREVENT Trial - Design and Rationale
- Asian Multicenter Registry
- FFR Guided Clinical Practice of Left Main PCI
- [FFR Use at CathLab: More & Better] FFR-guided PCI in Routine Practice: Lessons from the AMC Experience
- Temporal Trends and Outcomes of Contemporary LM Treatment: From the Asan Left Main Registry
- Either FFR or IVUS Is Acceptable, but Choose Your Cutoff Values Wisely!
- 15-year Temporal Change of LM Revascularization: Lesson from Asan Main Registry
- Do You Want to Treat?: Functionally Insignificant Vulnerable Plaque - No, I Don\'t. We Can\'t Predict Fate of Vulnerable Plaque.
- Meta-analysis of LM PCI: PCI Using DES vs. CABG
- How Good FFR Guided in Real Practice: Data from Asan PCI and Multivessel Registry
- IVUS-MLA and FFR
- Coronary Angiography versus FFR: Why Mismatches
- [Functionally Insignificant, Vulnerable Plaque: Do You Want to Treat?] No, I Don't
- TAVI in Korea: How to Avoid Conduction Disturbance..
- PCI vs CABG from BARI to SYNTAX: Is the Game over?
- Functional Evaluation Is Necessary !
- Impact of Functional Angioplasty in Our Real Practice!
- Impact of Functional Angioplasty to Current Practice: Trends in Clinical Outcomes of PCI with Drug Eluting Stents
- Featured Lecture: The Fate of PCI for Multi-Vessel Disease in the Era of COURAGE, SYNTAX, FAME, and FREEDOM
- Now, Do the IVUS-MLA Criteria Need to Be Adjusted ?
- When and How We Utilize Imaging and Functional Information in LM Stenting
- Clinical Outcomes from RCTs and Registries
- Why Visual-functional Mismatch? New Insight from Computational Simulation and Imaging Data
- New Frontiers in Left Main Intervention; Functional Angioplasty and New Optimizing Criteria
- Why Visual-functional Mismatches?
- FFR Guided and IVUS Supported Functional Angioplasty
- Device Positioning Is Crucial.
- Functional PCI for LM Stenosis: IVUS and FFR Guided
- [Debate: Can We Safely Defer PCI Just Based on FFR>0.80?] Yes, Already Proven.
- Functional Angioplasty - Insight from FFR and IVUS
- Why Visual-Functional Mismatches?
- Invited Case Presentation & Focus Review: FFR Guided Spot Stenting for Tandem Lesion PCI
- Discrepancy between Anatomic vs. Functional Parameters (IVUS vs. FFR)
- It's Not Enough !
- Long and Tandem Lesion Intervention: FFR Guided Spot Stenting
- Pre-COMBAT: LM Disease Revascularization - PCI vs. CABG Randomization Study
- Is Angiography Enough To Guide LMT PCI? - 'Functional Approach Should Be Considered!'
- Left Main PCI: Where We Are? Where We Are Going?
- Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease
- Anatomic vs. Functional Assessment of Coronary Artery Stenosis: Can IVUS-Derived Minimal Lumen Area Predict FFR < 0.8?
- Case Based Learning
- Paradigm Shift to Functional Angioplasty: FFR Guided Decision Making, IVUS Guided Optimization
- PCI in Unprotected Left Main Disease (MAIN-COMPARE, SYNTAX, and Several Registries)
- Xience V in Real Life
- Duration of Dual Antiplatelet Therapy in DES
- Insight into LM PCI from Main-COMPARE, SYNTAX LM, and Registries
- Coronary Intervention
- Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation
- DECISION CTO_New Horizon in CTO Treatment; Randomized Study Proposal
- Comparison of Sirolimus- and Paclitaxel-Eluting Stents vs Zotarolimus-Eluting Stents in Real World Practice: The ZEST Randomized Controlled Trial
- Future Clinical Study for Nobori Stent in Korea
- The Impact of Diabetes in the DES Long-Term Outcome
- Prognostic Influence of DM on Long-Term Clinical Outcomes and Stent Thrombosis Following DES Implantation in Asian: AMC Experience
- Can SYNTAX Score Be Feasible to Predict Outcomes of LM Revascularization?: Application to MAIN-COMPARE Registry
- Can Carotid Artery Stenting Before CABG Reduce Perioperative Stroke ?
- Tailores Approach with DES for Long Coronary Lesions
- \"ZEST\" Trial
- PCI vs CABG in Left Main Disease: Main Registry Update
- Impact of Diabetes on Long-Term Outcomes of Drug-Eluting Stents in Asian Patients
- Long-Term Evaluation of DES vs. BMS; 10-Year Experience from Single Center Registry
- How Can We Optimize Good Result in the Long Coronary Lesion ?
- Left Main Trifurcation Intervention
- LM Intervention Is Still an Available Option Despite Late Stent Thrombosis?
- VH-IVUS: Matched and Mismatched
- Nobori Stent, Update
- VH Experience in Real World: Asan Medical Center
- How to Treat - Unprotected Left Main Disease
- LM Bifurcation Intervention Guideline for COMBAT
- Safety and Efficacy of Cypher on Complex Lesion
- LM stenting -Cypher
- Drug Eluting Stent: Real World Experience(AMC Registry Study)
- Long Cypher Multicenter Registry Study
- Aggressive Colesterol Lowering Therapy after PCI(Percutaneous Coronary Intervention)
- Long-DES: Study presented in TCT 2004
- Treatment of In-Stent Restenosis : Drug Eluting Stent versus Brachytherapy
- Is bypass surgery needed for elderly patients with left main coronary artery disease? - CON l
- Safety and Effectiveness of Sirolimus Eluting Stent for Left Main Coronary Artery Stenosis
- Long Cypher?Multicenter Registry Study in Korea
- Bail-out stenting for Unprotected Left Main Coronary Artery Dissection during Catheter-Based Procedure
- Cypher vs. Taxus ; Taxus vs. Cypher - Is there something different ?
- Primary Stenting for Unprotected Left Main Coronary Artery Stenosis during AMI
- Percutaneous Mitral Valvuloplasty: State of Art
- Coronary Perforation of Proximal LAD after Debulking for LMCA Ostial Stenosis, Treated with PTEE-covered JoStent
- Why Polymer Coated Paclitaxel Stents
- Percutaneous Intervention of Unprotected left main Disease
- Technical Feasibility, Safety, and Clinical Outcome of Stenting of Unprotected Left Main Coronary Artery Bifurcation Narrowing Equipment Overview of DCA Device Percutaneous Intervention of Unprotected Left Main Disease
- PCI for Chroic Total Occlusion
- Drug-Eluting Stent
- Left Main Ostial Stenosis after Aortic Valve Replacement
- Percutaneous Intervention of Unprotected Left Main Ostial and Shaft Disease